AZN: 4,205.62 -73.00 (▼1.71%)

Delayed:2016-12-12 18:15:00
Bid Price 4,206.00 High Price 4,297.29
Ask Price 4,208.00 Low Price 4,176.00
Open Price 4,259.00 Spread 0.05%
Prev Close 4,206.00 Volume 3,492,357.00

AstraZeneca Share Price Chart


Historic – 1 year

AstraZeneca Share Price Information

Name AstraZeneca Epic AZN
Sector Pharmaceuticals & Biotechnology ISIN GB0009895292
Activites One of the world’s leading pharmaceutical companies. Security Type Equity

Key numbers

Latest Share Price (p) 4,207.00 Net Gearing (%) 58.84
Market Cap (£m) 52,069.52 Gross Gearing (%) 69.22
Shares in issue (m) 1,265.05 Debt Ratio 59.10
P/E Ratio 18.46 Debt-to-Equity Ratio 0.64
Divs per share (p) 188.50 Assets / Equity Ratio 3.25
Dividend Yield (%) 4.85 Price to book value 2.81
Dividend Cover 2.79 SROCE (%) 6.78
Earning per share (p) 223.00 EPS Growth (%) 127.55
52-week high / low (p) 5,505.00 / 3,680.00 DPS Growth (%) 5.84

AstraZeneca Broker Views

Date Broker Rec. Price Old target price New target price Notes
12 Dec Shore Capital Hold 4,205.62 Retains
12 Dec JP Morgan Cazenove Neutral 4,205.62 Reiterates
12 Dec Deutsche Bank Buy 4,205.62 Retains
09 Dec Shore Capital Hold 4,205.62 Retains
08 Dec Liberum Capital Hold 4,205.62 5200.00 5200.00 Reiterates

AstraZeneca Director Deals

Date Director Type Volume / Price Trade Value
01 Nov 2016 Graham Chipchase Buy 100 @ 4807.95p £4,807.95
01 Aug 2016 Marc Dunoyer Transfer In 43730 @ 0.00p £0.00
14 Jun 2016 Pascal Soriot Transfer In 84316 @ 0.00p £0.00

AstraZeneca Company News

FTSE boosted by utilities, miners and M&A;

The FTSE 100 was 0.3% higher as United Utilities (UU.) rose by 1.5%. Miners Fresnillo (FRES) and Antofagasta (ANTO) supported the blue chip index with gains of up to 1.3%.

There were a flurry of last-minute corporate updates, notably from Sky (SKY) and AstraZeneca (AZN).

Imperial Brands (IMB) was also a key blue chip mover, rising 1.9%.

West Texas Intermediate crude oil advanced 1% to $51.34 and Brent crude oil nudged 0.3% to $54 per barrel, respectively.

Gold slumped 0.8% to $1,160 per ounce and copper gained 1.3% to $5,842 per tonne.


Pay TV giant Sky (SKY) has received a takeover approach from 21st Century Fox of £10.75 per share in cash, causing its share price to rocket 26.7% higher to £10.

AstraZeneca (AZN) received a boost after the US Food and Drug Administration accepted the first Biologics License Application for durvalumab, a PD-L1 human monoclonal antibody.

Communication services group WPP (WPP) reported its operating PR firm Burson-Marsteller acquired a minority stake in its Kenyan affiliate, Engage Burson-Marsteller.


Home credit business International Personal Finance (IPF) crashed 43.5% after the Polish government proposed to further crack down on how much lenders can charge.

Specialist publisher Euromoney Institutional Investor (ERM) fell 6.2% to £10.50 as parent Daily Mail & General Trust (DMGT) confirmed plans to put 32.3 million shares in the business up for sale at 975p. DMGT said it wants to reduce its stake from 67% to 49% for £315m.

Trading platforms CMC Markets (CMCX) and IG (IGG) tumbled into negative territory after a possible ban on selling contract for difference products to retail customers was announced yesterday. The ban may be enforced if people can lose more money than they have in their account.

Landscaping products manufacturer Marshalls (MSLH) revealed a flat order book for domestic installers at the end of October, prompting a 6.3% decline in the stock.

Textile service business Berendsen (BRSN) announced its UK Cleanroom business is under investigation by the Competition and Markets Authority, in relation to agreements with a joint venture in 2012.


Financial services provider Fairpoint (FRP) issued a profit warning for the full year as trading in legal services were lower in November and expected to remain lower this month. The stock plummeted 61% to 20.5p.

Shares in Northacre (NTA) nudged 5% lower following an initial rise, after announcing it intends to seek shareholder approval to stop trading on AIM.

Medical device company Creo Medical (CREO) got a shot in the arm on its first day of trading on AIM, as the stock gained approximately 5% to 80p.

The oldest fruit brand in the world Fyffes (FFY) bloomed 44.4% to 186p on a recommended cash offer of €2.23 (189p) per share from Japanese conglomerate the Sumitomo Corporation.

Market researcher Brainjuicer (BJU) delivered good news to investors as full year profit is expected to be ahead of expectations due to stronger trading and the weak pound.

Photo booth operator Photo-Me International (PHTM) hiked its dividend by a fifth to 3.09p per share as pre-tax profit rose by a fifth from £25.8m to £31m.

Premier African Minerals (PREM) decided not to exercise its option to acquire up to 30% in Casa Mining, boosting the stock by 8%.

Information management software supplier Ideagen (IDEA) announced the acquisition of IPI Solutions for £5.54m.

Story provided by

FDA accepts AZ’s durvalumab for BLA in bladder cancer

AstraZeneca and its global biologics research and development arm, MedImmune, says the US Food and Drug Administration has accepted the first biologics licence application (BLA) for durvalumab, a PD-L1 human monoclonal antibody (mAb), and granted priority review status with a Prescription Drug User Fee Act (PDUFA) set for the second quarter of 2017.

The BLA submission, for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has progressed during or after one standard platinum‑based regimen, is based on the results of the UC cohort of Study 1108 and follows the FDA’s February 2016 Breakthrough Therapy Designation for durvalumab.

At 3:16pm: (LON:AZN) AstraZeneca PLC share price was +232.25p at 4348.25p

Story provided by

Trial shows AZ’s Tagrisso superiority over chemotherapy

AstraZeneca today presented data which show that Tagrisso (osimertinib) could replace chemotherapy as the standard of care for lung cancer patients.

AstraZeneca presented data from the AURA3 trial that is supportive of Tagrisso (osimertinib) potentially becoming the new standard of care for second-line treatment of patients with epidermal growth factor receptor (EGFR) T790M mutation-positive locally-advanced or metastatic non-small cell lung cancer (NSCLC).

The first randomised Phase III data showed that Tagrisso second-line therapy improved progression-free survival (PFS) by 5.7 months compared with standard platinum-based doublet chemotherapy (Hazard Ratio [HR]=0.3).

The results were presented at the 17th World Conference on Lung Cancer (WCLC) in Vienna, hosted by the International Association for the Study of Lung Cancer, and published simultaneously online in The New England Journal of Medicine.

AstraZeneca executive vice-president, global medicines development and chief medical officer, Sean Bohen, said: “The confirmatory Phase III data suggest the potential for Tagrisso to replace chemotherapy as the standard of care for patients who have progressed following EGFR tyrosine kinase inhibitor treatment. As lung cancer is the most common type of cancer to spread to the brain, it is also encouraging to see the activity of Tagrisso in patients with central nervous system metastases whose prognosis is often particularly poor.”

At 9:45am: (LON:AZN) AstraZeneca PLC share price was -22.5p at 4011p

Story provided by

FTSE mixed with blue chips up on miners

London stocks were mixed in early deals as the market continued to digest news of Italy’s Prime Minister, Matteo Renzi, quitting after losing a key constitutional reform referendum, sparking a slide in the euro.

Soon after the open, FTSE 100 was down 17.06 points, or 0.25%, to 6747.78, while FTSE 250 was down 3.2, or 0.02%, to 17,432.1. At 8.35am, WTI crude was up 0.41% to $51.89/bbl and Brent was up 0.42% to $54.69/bbl. Gold was down 0.43% to $1172.7/oz.

Miners led blue chips up. BHP BIlliton (BLT) rose 2.45% to 1336p, while Antofagasta (ANTO) added 2.45% to 710.5p. More — among them Rio Tinto (RIO), Glencore (GLEN) and Anglo American (AAL) — followed close behind.

So far, top-100 index risers outnumbered fallers about 87 to 13. Among those on the march north were supermarkets, leisure, financials and property. Burberry (BRBY) added 2.44% to 1446.5p, while Tesco (TSCO) improved 1.93% higher to 210.75p.

In the leisure sphere, TUI (TUI) rose 1.45% to 1050p, with Carnival (CCL) firming 1.15% to 3952p. Financials were guided up by Prudential (PRU), ahead 1.67% to 1587p, and Barclays (BARC), which improved 1.67% to 216.5p.

Among those to the downside, gold sensitive miners were notable. Randgold Resources (RRS) flopped 3.39% to 5627.5p, while Fresnillo (FRE) faded 2.92% to 1163p. Several US rates-sensitive utilities also figured behind Centica (CNA), lower 0.5% to 207.15p.


Royal Bank of Scotland (RBS), up 0.26% to 193.9p, said it has concluded a full and final settlement with three of the five shareholder groups representing 77% of the claims by value in the 2008 Shareholder Rights Issue litigation.

AstraZeneca (AZN), up 0.3% to 4067.25p, has completed the agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the US.


Mirada (MIRA), down 42.42% to 2.38p, now expects total revenues for the current financial year will be below current market views, with pretax profits likely to be substantially lower than current market anticipations.

Origo Partners (OPP), up 15.38% to 1.88p, has entered into an unsecured loan agreement with Lars Bader, under which the latter has provided a $2.5m unsecured loan.


Purplebricks (PURP), up 7.6% to 113.25p, has more than halved its H1 pretax loss to £2.76m, from £6.39m. Revenue was £18.7m, from £7.2m. Cambian Group (CMBN), up 11.66% to 146p, has agreed to dispose of its adult services business to Cygnet Health Care Ltd, a subsidiary of Universal Health Services for £377m cash.

Armadale Capital (ACP), up 10.34% to 4p, said Kisenge Mining Pty Ltd has completed due diligence and exercised its option to form a JV with Armadale to develop and operate the Mpokoto gold project in the Katanga Province of the Democratic Republic of Congo.

RedstoneConnect (REDS), up 7.27% to 1.48p, announces the deployment of award-winning workspace management software solution OneSpace with UBM, a global events and marketing communications specialist, at their US head office in New York City.

RhythmOne (RTHM), up 6.35% to 39.88p, has agreed to acquire all of Perk’s issued and outstanding Common and Class A Restricted voting shares and certain employee options in exchange for total consideration of about $42.5m in an all stock transaction that is expected to close in January 2017.

Westminster Group (WSG), up 5.81% to 20.5p, said division Sovereign Ferries is ready to commence its ferry service in Sierra Leone, West Africa.

Flowgroup (FLOW), up 5.08% to 7.75p, has issued a further update to its Flow Energy business, which as stated on 16 November continues to perform well and in line with management expectations.

CyanConnode (CYAN), up 4.76% to 0.22p, has announced a further purchase order from Larsen & Toubro to expand the deployment of CyanConnode’s smart metering solution at Tata Power Mumbai with an additional 4,700 smart meters.

Other stocks in the news included Helios Underwriting (HUW), ECO Animal Health (EAH), St. Modwen (SMP), Spectra Systems (SPSY), Filtronic (FTC), Sula Iron & Gold (SULA), Horizonte Minerals (HZM), Evgen Pharma (EVG), 21st Century Technology (C21), Physiomics (PYC), Landore (LND), Wizz Air (WIZZ), Gulf Keystone (GKP), Craven House Capital (CRV) and Aminex (AEX).

Story provided by

AZ completes agreement on Rhinocort Aqua rights

AstraZeneca has completed the agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the US.

Rhinocort Aqua is a nasal spray indicated for allergic and non-allergic rhinitis (inflammation of the inside of the nose), and for the treatment of nasal polyps (swelling of the nasal lining).

Under the terms of the agreement, AstraZeneca has received a payment of $330 million from Cilag GmbH International for the rights to the medicine outside the US.

As AstraZeneca will not maintain a significant ongoing interest in Rhinocort Aqua, the payment will be recognised as Other Operating Income in the Company’s financial statements, and will be booked in the fourth quarter of 2016.

Story provided by